latest news releases from the newsroom
Nomination Committee for 2006 Annual Shareholders' Meeting of Skanska AB
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In accordance with a decision in the Skanska's Annual Shareholders' Meeting 2005, the Chairman of the Board has asked five of the largest shareholders to appoint one representative each that, together with the Chairman will form a Nomination Committee. The task of the Nomination Committee is to propose a Board of Directors and also remuneration to the Board of Directors. The proposals are to be decided upon in the Annual Shareholders' Meeting 2006.
Active Biotech: Confirmed ANYARA Tumor PET Localization in Cancer Patients
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using Positron Emission Tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating that ANYARA localizes to tumors that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, UK and the first results from this study will be presented at the NCRI (National Cancer Research Institute) conference held in Birmingham, UK on October 2-5.
Port of Houston Authority
PHA Commission Delivers Bayport, Security, Capital Improvement Matters
HOUSTON, Sept. 29, 2005 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission approved several recommendations involving contract awards, bids and proposals, professional services and general administrative and operational matters during its public meeting on Thursday, September 29, 2005. Chairman Jim Edmonds presided over the meeting with Vice Chairman Kase Lawal, Commissioner Steve Phelps, Commissioner Jim Fonteno, Commissioner Jimmy Burke, Commissioner Cheryl Thompson-Draper, and Commissioner Janiece Longoria.
Integra LifeSciences Holdings Corp.
Integra LifeSciences Acquires Eunoe Inc.'s Intellectual Property Estate
PLAINSBORO, N.J., Sept. 29, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has acquired the intellectual property estate of Eunoe, Inc. Prior to ceasing operations, Eunoe, Inc. was engaged in the development of its innovative COGNIShunt(R) system for the treatment of Alzheimer's disease patients. The COGNIShunt(R) system was evaluated under an FDA Investigational Device Exemption.